Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Whitbread Surges On Costa Coffee Sale

Fri, 31st Aug 2018 10:36

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Whitbread, up 16%. The hospitality firm said it agreed the sale of its Costa Coffee business to US soft drinks giant Coca-Cola Co at an enterprise value of GBP3.90 billion. Whitbread, which also owns the Premier Inn hotel chain, is expecting net proceeds of GBP3.80 billion, and said most of this will be returned to shareholders. The sale, the company continued, will reduce debt and also allow for an increased pension contribution and further expansion of Premier Inn in both the UK and Germany. Whitbread believes a "substantial" premium would have been created by its planned demerger of Costa Coffee, which was announced in April this year. At the time the company had described itself as "committed" to demerging Costa after the coffee chain saw a decline in annual profit.----------FTSE 100 - LOSERS----------Sage Group, down 6.5%. The accounting software provider said Chief Executive Officer Stephen Kelly has stepped down from his role with immediate effect. He is to "remain available to the group" until May 31, 2019. Kelly has been chief executive of Sage for nearly four years since 2014. The FTSE 100 group has started the process to find a new chief executive. Chief Financial Officer Steve Hare has been given the additional post of chief operating officer on an interim basis, giving him full authority to run the business until a new chief executive is appointed. In addition, Sage said it has continued to trade in line with its full-year guidance of 7.0% organic revenue growth and a 27.5% organic operating margin. The group said achieving this guidance is dependent on the closing of several Enterprise Management opportunities in September.----------Evraz, down 1.5%, Glencore, down 1.2%, BHP Billiton, down 0.9%. The commodity stocks were lower amid concerns that the US-Chinese trade dispute may intensify and over metal tariffs. US President Donald Trump said he could move ahead with a plan to impose tariffs on USD200 billion in Chinese imports as early as next week. In addition, Trump also threatened to pull out from the World Trade Organization and called European trade policies "almost as bad as China," raising fresh worries over trade friction.----------FTSE 250 - WINNERS----------Hays, up 6.4%. Shares in the recruiter were rebounding after it expressed uncertainty for its UK market due to economic instability, despite reporting positive results for its recently ended financial year on Thursday. The stock closed down 4.7% on Thursday. ----------FTSE 250 - LOSERS----------Serco Group, down 3.1%. Exane BNP downgraded the outsourcer to Neutral from Outperform.----------OTHER MAIN MARKET AND AIM - WINNERS----------Midatech Pharma, up 31%. The rare disease-focused pharmaceutical company announced positive data from its proof of concept exploratory study for its key oncology drug candidate MTD201. MTD201 Q-Ocreotide is a sustained-release treatment for carcinoid cancer and acromegaly. In a a double-blind exploratory study, the tolerability, pharmacokinetics and growth hormone profiles after a 30 milligram injection in 24 healthy subjects were compared between MTD201 and Novartis AG's Sandostatin LAR. Results from the study indicated that MTD201 produces a safe sustained-release profile of octreotide with growth hormone levels suppressed by an average of 25%, comparable with Sandostatin. Midatech will now seek regulatory approval for MTD201 as an equivalent product of improved product to Sandostatin in preparation for a follow-on trial.----------OTHER MAIN MARKET AND AIM - LOSERS----------FFI Holdings, down 27%. The entertainment industry contract provider said profit halved as costs associated with its recently listing hurt despite revenue jumping on acquisitions. For the year ended March 31, pretax profit halved to USD5.3 million from USD10.3 million the year prior. This was despite revenue rising to USD58.9 million from USD38.8 million the year before. Profit performance was hurt by a sharp rise in administrative and exceptional costs. Administrative expenses rose to USD29.4 million from USD18.9 million the year prior primarily driven by a jump in staff costs. Exceptional costs also rose to USD10.7 million from USD1.9 million the year before which was chiefly related to USD9.5 million in initial public offering costs.----------
More News
13 Jun 2022 16:00

UK shareholder meetings calendar - next 7 days

Tuesday 14 June 
Andrews Sykes Group PLCAGM
Coro Energy PLCAGM
DCD Media PLCGM re de-listing from AIM
Everyman Media Group PLCAGM
Fair Oaks Income LtdAGM
Genflow Biosciences PLCAGM
IP Group PLCAGM
LoopUp Group PLCAGM
Pod Point Group Holdings PLCAGM
SDX Energy PLCAGM
Somero Enterprises IncAGM
St Mark Homes PLCAGM
Wednesday 15 June 
Angling Direct PLCAGM
888 Holdings PLCAGM
Christie Group PLCAGM
Deltic Energy PLCAGM
Distribution Finance Capital Holdings PLCAGM
Ferrexpo PLCAGM
Foresight Solar Fund LtdAGM
Foxtons Group PLCAGM
IGas Energy PLCAGM
NAHL Group PLCAGM
NB Global Monthly Income Fund LtdAGM
Phoenix Spree Deutschland LtdAGM
Science in Sport PLCAGM
SourceBio International PLCAGM
Standard Life Investments Property Income Trust PLCAGM
Tortilla Mexican Grill PLCAGM
WANdisco PLCAGM
Whitbread PLCAGM
Xaar PLCAGM
Thursday 16 June 
AEX Gold IncGM re name change to Amaroq Minerals Ltd
AEX Gold IncAGM
Anexo Group PLCAGM
Anpario PLCAGM
Baillie Gifford China Growth Trust PLCAGM
Bisichi PLCAGM
Engage XR Holdings PLCAGM
EPE Special Opportunities LtdAGM
Evraz PLCAGM
Informa PLCAGM
Kape Technologies PLCAGM
Martin Currie Global Portfolio Trust PLCAGM
Ruffer Investment Co LtdEGM re authority to issue shares
S4 Capital PLCAGM
TBC Bank Group PLCAGM
UK Commercial Property REIT LtdAGM
Friday 17 June 
Blackstone Loan Financing LtdAGM
boohoo Group PLCAGM
Directa Plus PLCAGM
Tesco PLCAGM
EnQuest PLCAGM
Octopus Renewables Infrastructure Trust PLCAGM
Monday 20 June 
Armadale Capital PLCAGM
Bank of Georgia Group PLCAGM
Globalworth Real Estate Investments LtdAGM
MetalNRG PLCAGM
Midatech Pharma PLCAGM
Silver Bullet Data Services Group PLCGM re fundraise
Venture Life Group PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
10 Jun 2022 12:25

Midatech taps Stephen Parker as its new chairman

(Sharecast News) - Biotechnology company Midatech Pharma announced on Friday that its chairman and non-executive director Rolf Stahel intends to retire after its annual general meeting on 20 June.

Read more
10 Jun 2022 11:19

Midatech Chair Rolf Stahel retires; Stephen Parker named as successor

(Alliance News) - Midatech Pharma PLC on Friday said that Chair Rolf Stahel plans to leave the board on June 20, and it named Stephen Parker as his successor.

Read more
1 Jun 2022 13:59

IN BRIEF: Midatech Pharma gets fast track to develop glioblastoma cure

Midatech Pharma PLC - Cardiff-based biotechnology company focused on improving the bio-delivery and biodistribution of medicines - Receives fast track designation from the US Food & Drug Administration for its development programme of MTX110 for the treatment of recurrent glioblastoma.

Read more
26 Apr 2022 18:03

TRADING UPDATES: Billington faces headwinds; Immotion plans spin-off

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
14 Apr 2022 21:36

TRADING UPDATES: Polar Capital assets up; Brooks Macdonald funds fall

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
9 Mar 2022 14:26

Midatech extends work with Janssen to another experimental molecule

(Sharecast News) - Drug delivery technology company Midatech Pharma announced an extension of its existing research and development collaboration with Johnson & Johnson subsidiary Janssen Pharmaceuticals, agreed in July 2020.

Read more
9 Mar 2022 12:18

TRADING UPDATES: Mothercare distances from Russia; Midatech's J&J deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
17 Jan 2022 17:04

TRADING UPDATES: CentralNic and Pebble tip 2021 earnings rise

TRADING UPDATES: CentralNic and Pebble tip 2021 earnings rise

Read more
13 Dec 2021 13:07

Midatech shares rise as cancer drug gets Phase 1 approval by US FDA

Midatech shares rise as cancer drug gets Phase 1 approval by US FDA

Read more
17 Sep 2021 12:28

Midatech Pharma interim losses narrow

(Sharecast News) - Drug delivery technology Midatech Pharma significantly narrowed interim losses in the six months ended 30 June ahead of discussions aimed at licensing its products to drugmakers.

Read more
17 Sep 2021 10:37

Midatech Pharma interim loss narrows as prepares for licence talks

Midatech Pharma interim loss narrows as prepares for licence talks

Read more
10 Sep 2021 16:09

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
29 Jun 2021 17:10

TRADING UPDATES: Gaming Realms BetMGM deal; Argo bitcoin-backed loan

TRADING UPDATES: Gaming Realms BetMGM deal; Argo bitcoin-backed loan

Read more
29 Jun 2021 10:53

Midatech raises £10m to continue formulation development

(Sharecast News) - Drug delivery technology company Midatech Pharma has raised £10m before expenses, it announced on Tuesday, to continue its formulation development work.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.